Cardiovascular Systems Expands Product Portfolio
April 08 2009 - 8:30AM
Business Wire
Cardiovascular Systems, Inc. (CSI) (Nasdaq:CSII), a medical
device company developing and commercializing innovative
interventional treatment systems for vascular disease, has expanded
its product portfolio by signing an agreement with Invatec, a
comprehensive provider of interventional products, to market
Invatec�s PTA balloon catheter line in the United States. CSI is
also launching the newest addition to its Viper line of
supplemental products, the ViperSheath� Introducer Sheath.
CSI�s flagship product is the Diamondback 360o� Orbital
Atherectomy System, a minimally invasive catheter system for
treating peripheral arterial disease (PAD). Between 8 and 12
million Americans suffer from PAD, which is caused by the
accumulation of plaque in leg or foot arteries, reducing blood
flow. Symptoms include leg pain when walking or at rest, and PAD
can lead to tissue loss and eventually limb amputation. The
Diamondback 360o is highly effective in removing plaque and
restoring blood flow in vessels both below and above the knee. In
some cases, balloon angioplasty may also be used to achieve the
desired vessel diameter after removing plaque with the Diamondback
360o.
�CSI is committed to developing and offering products
specifically designed to treat PAD and to prevent the trauma and
costs associated with limb amputation,� said David L. Martin, CSI
president and chief executive officer. �The innovative Invatec
products and Viper line of supplemental products, including the new
ViperSheath, complement and expand our product portfolio, as well
as enhance the productivity of our national sales team. These
product additions are in line with our mission to provide
physicians with the tools they need to treat PAD.�
CSI will offer the Invatec balloon catheter line, including the
SubMarine Plus� PTA Balloon Catheter, the Admiral Xtreme� PTA
Balloon Catheter and the Amphirion Deep� PTA Balloon Catheter.
Dr. Ray Dattilo, director of peripheral interventions at St.
Francis Hospital, Topeka, Kansas, said, �The large diseased vessels
above the knee will often become damaged when ballooned, if they
are not first made more compliant with Diamondback 360o treatment.
We find the Invatec balloons expand with far less pressure after
the vessel is treated with the Diamondback 360o, avoiding both
dissection and the need to stent.�
�The extensive reach of CSI's sales and marketing team will
enable us to fully capitalize on the significant market interest in
Invatec's balloon catheter line,� said Jack Springer, president of
Invatec USA. �CSI is the ideal partner for us, as it shares our
belief in working closely with our physician community to develop
endovascular tools that help improve the outcomes of their patients
and enhance the quality of their lives.�
CSI Expands Product Portfolio with ViperSheath�
Launch
Additionally, CSI is launching ViperSheath, an introducer sheath
providing a smooth, pliable solution for vessel access. A tapered
soft tip means low insertion force and minimal trauma on vessel
walls during insertion. A kink- and crush-resistant catheter allows
for optimal crossability and easy navigation of tortuous vessels.
ViperSheath joins a portfolio of existing CSI supplemental products
including: ViperSlide� � an exclusive lubrication designed to
optimize the smooth operation of the Diamondback 360�; ViperTrack�
� a radiopaque tape designed to assist in identifying lesion
lengths and the best treatment strategy for procedures using
fluoroscopic or radiographic imaging, and ViperWire� a spring tip
guidewire with flexible or firm stiffness profiles, specifically
designed for the Diamondback 360�� to achieve maximum performance.
All products are available through the CSI national sales
organization.
About Cardiovascular Systems Inc.
Cardiovascular Systems Inc. is a medical device company focused
on developing and commercializing interventional treatment systems
for vascular disease. The company�s Diamondback 360� Orbital
Atherectomy System is capable of treating a broad range of plaque
types both above and below the knee, including calcified vessel
lesions, and addresses many of the limitations associated with
existing treatment alternatives. In August 2007, the U.S. FDA
granted 510(k) clearance for the use of the Diamondback 360� as a
therapy for PAD (peripheral arterial disease), and CSI commenced a
U.S. product launch in September 2007. The Diamondback 360� system
has been adopted by more than 400 hospitals across the United
States. For more information visit the company�s Web site at
www.csi360.com.
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cardiovascular Systems (NASDAQ:CSII)
Historical Stock Chart
From Jul 2023 to Jul 2024